The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 501–600 of 1,006
Chen, X., Chen, T., Ji, F., Zhou, Y., & Yin, S. (2015) · Catalysis Science & Technology · doi:10.1039/c4cy01618a · Cited by 61
Firth, N. C., Atrash, B., Brown, N., & Blagg, J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00073 · Cited by 85
Multi-objective optimization methods in novel drug design
Lambrinidis, G., & Tsantili‐Kakoulidou, A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1867095 · Cited by 71
“cept cutoff values or favorable ranges are defined for molecular characteristics, essential for drug action and safety, thus projecting biological complexity to the simplicity of ‘rules of thumb’ [13,14].”
BackgroundRoskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105579 · Cited by 63
Modeling Cellular Pharmacokinetics of 14- and 15-Membered Macrolides with Physicochemical Properties
Stepanić, V., Koštrun, S., Malnar, I., Hlevnjak, M., Butković, K., Ćaleta, I., Dukši, M., Kragol, G., Stegić, O. M., Mikac, L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101317f · Cited by 60
Schulze, V., Klar, U., Kosemund, D., Wengner, A. M., Siemeister, G., Stöckigt, D., Neuhaus, R., Lienau, P., Bader, B., Prechtl, S., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02035 · Cited by 60
Recent Trends and Observations in the Design of High-Quality Screening Collections
Renner, S., Popov, M., Schuffenhauer, A., ROTH, H. ‐., Breitenstein, W., Marzinzik, A. L., Lewis, I., Krastel, P., Nigsch, F., Jenkins, J. L., et al. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.15 · Cited by 61
Kell, D. B. (2012) · BioEssays · doi:10.1002/bies.201100144 · Cited by 70
“Drug discovery is a tricky and costly process [42], and nowadays usually involves the search for a molecule that can bind tightly to (and inhibit) a chosen molecular target.”
Brodney, M. A., Barreiro, G., Ogilvie, K., Hajós‐Korcsok, É., Murray, J. C., Vajdos, F. F., Ambroise, C., Christoffersen, C. L., Fisher, K. E., Lanyon, L. F., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3009426 · Cited by 66
Alelyunas, Y. W., Liu, R., Pelosi-Kilby, L., & Shen, C. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.007 · Cited by 61
Xie, L., Zhang, L., Wang, C., Wang, X., Xu, Y.-M., Yu, H., Wu, P., Li, S., Han, L., Gunatilaka, A. A. L., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716046115 · Cited by 60
“0) have been correlated with higher success rates in market introduction due to more favorable drug potency, bioavailability, pharmacokinetics, and toxicity profiles (50).”
BackgroundVleet, T. R. V., Liguori, M. J., Lynch, J. J., Rao, M. S., & Warder, S. E. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218799713 · Cited by 68
Ritchie, T. J., Luscombe, C. N., & Macdonald, S. J. F. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800429e · Cited by 62
A systematic approach to diverse, lead-like scaffolds from α,α-disubstituted amino acids
Foley, D. J., Doveston, R. G., Churcher, I., Nelson, A. S., & Marsden, S. P. (2015) · Chemical Communications · doi:10.1039/c5cc03002a · Cited by 59
Brooks, C. A., Barton, L. S., Behm, D. J., Eidam, H. S., Fox, R. M., Hammond, M., Hoang, T. H., Holt, D. A., Hilfiker, M. A., Lawhorn, B. G., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00274 · Cited by 65
Osborne, J., Panova, S., Rapti, M., Urushima, T., & Jhoti, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190694 · Cited by 58
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
Luker, T. J., Alcaraz, L., Chohan, K. K., Blomberg, N., Brown, D. S., Butlin, R. J., Elebring, T., Griffin, A. M., Guile, S. D., St-Gallay, S. A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.074 · Cited by 60
Self-citationMakam, P., & Kannan, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.086 · Cited by 63
Size estimation of chemical space: how big is it?
Drew, K. L. M., Baiman, H., Khwaounjoo, P., Yu, B., & Reynisson, J. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01424.x · Cited by 62
Falconer, S. B., Reid‐Yu, S. A., King, A. M., Gehrke, S. S., Wang, W., Britten, J. F., Coombes, B. K., Wright, G. D., & Brown, E. D. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00033 · Cited by 63
Enhanced Cellular Entry and Efficacy of Tat Conjugates by Rational Design of the Auxiliary Segment
Zhang, P., Lock, L. L., Cheetham, A. G., & Cui, H. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400619v · Cited by 59
Secondary pharmacology: screening and interpretation of off-target activities – focus on translation
Whitebread, S., Dumotier, B. M., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urbán, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.021 · Cited by 60
Cleghorn, L. A. T., Ray, P. C., Odingo, J. O., Kumar, A., Wescott, H., Korkegian, A., Masquelin, T., Moure, A. L., Wilson, C., Davis, S. H., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00172 · Cited by 59
Jordi, J., Guggiana-Nilo, D., Bolton, A. D., Prabha, S., Ballotti, K., Herrera, K. J., Rennekamp, A. J., Peterson, R. T., Lutz, T. A., & Engert, F. (2018) · Science Advances · doi:10.1126/sciadv.aav1966 · Cited by 73
Noji, S., Hara, Y., Miura, T., Yamanaka, H., Maeda, K., Hori, A., Yamamoto, H., Obika, S., Inoue, M., Hase, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00450 · Cited by 69
Towards the systematic exploration of chemical space
Dow, M., Fisher, M., JAMES, T. N., Marchetti, F., & Nelson, A. S. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob06098h · Cited by 58
2-Aminopyridine – an unsung hero in drug discovery
Rao, R. N., & Chanda, K. (2021) · Chemical Communications · doi:10.1039/d1cc04602k · Cited by 59
Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Polański, J., Kurczyk, A., Bąk, A., & Musioł, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167356 · Cited by 62
Orrling, K. M., Jansen, C., Vu, X. L., Balmer, V., Bregy, P., Shanmugham, A., ENGLAND, P. J., Bailey, D. S., Cos, P., Maes, L. J. R. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301059b · Cited by 58
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
Liang, J., Labadie, S. S., Zhang, B., Ortwine, D. F., Patel, S. D., Vinogradova, M. V., Kiefer, J. R., Mauer, T., Gehling, V. S., Harmange, J.-C., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.016 · Cited by 61
McIntyre, P. J., Collins, P. M., Vrzal, L., Birchall, K., Arnold, L. H., Mpamhanga, C., Coombs, P. J., Burgess, S. G., Richards, M. W., Winter, A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00537 · Cited by 58
A confidence predictor for logD using conformal regression and a support-vector machine
Lapins, M., Arvidsson, S., Lampa, S., Berg, A., Schaal, W., Alvarsson, J., & Spjuth, O. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0271-1 · Cited by 58
“Several studies have found that logD or logP of above 3 gives rise to promiscuity and risk for adverse in vivo toxicological outcomes [4, 6, 7].”
BackgroundHarrison, J. R., Brand, S., Smith, V., Robinson, D. A., Thompson, S., Smith, A., Davies, K., Mok, N. Y., Torrie, L. S., Collie, I. T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00884 · Cited by 58
Díaz-González, R., Luengo-Arratta, S. A., Seixas, J. D., Amata, E., Devine, W. G., Cordón-Obras, C., Rojas-Barros, D. I., Jiménez, E., Ortega, F., Crouch, S., et al. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003253 · Cited by 57
Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability
Buecheler, J. W., Winzer, M., Weber, C., & Gieseler, H. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.006 · Cited by 60
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design
Krieger, J., Sorrell, F. J., Wegener, A. A., Leuthner, B., Machrouhi, F., Hecht, M., Leibrock, E.-M., Müller, J. E., Eisert, J., Hartung, I. V., et al. (2023) · ChemMedChem · doi:10.1002/cmdc.202200615 · Cited by 61
The multiple roles of computational chemistry in fragment-based drug design
Law, R., Barker, O., Barker, J. J., Hesterkamp, T., Godemann, R., Andersen, O. A., Fryatt, T., Courtney, S., Hallett, D., & Whittaker, M. A. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9284-1 · Cited by 57
“Assessment of ligand-lipophilicity efficiency (LLE) from the point of a fragment hit, and beyond, and scoring optimized sets based on a measurement of cLogP per heavy-atom, can help to drive the development of series that will avoid failure due to hydrophobicity [ 59 ].”
BackgroundBagal, S. K., Omoto, K., Blakemore, D. C., Bungay, P. J., Bilsland, J., Clarke, P. J., Corbett, M. S., Cronin, C. N., Cui, J. J., Dias, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00280 · Cited by 57
Al-Ostoot, F. H., Zabiulla, Z., Salah, S., & Khanum, S. A. (2021) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-021-02172-5 · Cited by 59
Lugini, L., Federici, C., Borghi, M., Azzarito, T., Marino, M. L., Cesolini, A., Spugnini, E. P., & Fais, S. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1046062 · Cited by 56
Wyss, D. F., Wang, Y., Eaton, H. L., Strickland, C., Voigt, J. H., Zhu, Z., & Stamford, A. W. (2011) · Topics in current chemistry · doi:10.1007/128_2011_183 · Cited by 64
“Its LLE [29] was, however, significantly reduced due to its increased hydrophobicity.”
BackgroundKumar, A., Kumar, M., Maurya, S., & Khanna, R. S. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo5007762 · Cited by 56
Potent and Specific Inhibition of Glycosidases by Small Artificial Binding Proteins (Affitins)
Correa, A., Pacheco, S., Méchaly, A., Obal, G., Béhar, G., Mouratou, B., Oppezzo, P., Alzari, P. M., & Pecorari, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097438 · Cited by 68
“In vivo, a lack of selectivity for a drug can increase the risk of undesirable effects or even lead to toxicity [5] by off-target effects.”
BackgroundTosh, D. K., Finley, A., Paoletta, S., Moss, S. M., Gao, Z., Gizewski, E. T., Auchampach, J. A., Salvemini, D., & Jacobson, K. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501021n · Cited by 56
Lewis, M. L., & Cucurull-Sanchez, L. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9242-3 · Cited by 56
“Lipophilicity Efficiency (LLE) have recently being discussed [ 10 ].”
BackgroundUnderstanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Zhong, H., Mashinson, V., Woolman, T. A., & Zha, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990034 · Cited by 57
Drug efficiency indices for improvement of molecular docking scoring functions
García‐Sosa, A. T., Hetényi, C., & Maran, U. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21306 · Cited by 62
Rusinova, R., Herold, K. F., Sanford, R. L., Greathouse, D. V., Hemmings, H. C., & Andersen, O. S. (2011) · The Journal of General Physiology · doi:10.1085/jgp.201010529 · Cited by 56
“11), making it possible to explore a drug candidate’s bilayer-perturbing potential early in product development (Leeson and Springthorpe, 2007; Lundbæk, 2008).”
BackgroundChristiansen, E., Due‐Hansen, M. E., Urban, C., Grundmann, M., Schmidt, J., Hansen, S. V. F., Hudson, B. D., Zaibi, M. S., Markussen, S. B., Hagesæther, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301470a · Cited by 59
On the Solubility and Lipophilicity of Metallacarborane Pharmacophores
Rak, J., Dejlová, B., Lampová, H., Kaplánek, R., Matějíček, P., Cígler, P., & Král, V. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300565z · Cited by 56
Practical application of ligand efficiency metrics in lead optimisation
Scott, J. S., & Waring, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.004 · Cited by 63
Blaquière, N., Castanedo, G. M., Burch, J. D., Berezhkovskiy, L. M., Brightbill, H. D., Brown, S., Chan, C. C. C., Chiang, P., Crawford, J. J., Dong, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00678 · Cited by 56
Tomassi, S., Romanelli, A., Zwergel, C., Valente, S., & Mai, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00226 · Cited by 58
New quinoline NK3 receptor antagonists with CNS activity
Smith, P. W., Wyman, P. A., Lovell, P. J., Goodacre, C. J., Serafinowska, H. T., Vong, A. K. K., Harrington, F. P., Flynn, S. T., Bradley, D. M., Porter, R. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.005 · Cited by 56
Towards the realisation of lead-oriented synthesis
Doveston, R. G., Marsden, S. P., & Nelson, A. S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.006 · Cited by 55
Novel tactics for designing water-soluble molecules in drug discovery
Walker, M. A. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.960839 · Cited by 56
“As such, the term ‘Property-Based Drug Design’ has entered into the medicinal chemistry lexicon [1] indicating that physiochemical properties must be deliberately designed into a molecule and not left to chance [2-5].”
BackgroundInfluentialTwo ‘Golden Ratio’ indices in fragment-based drug discovery
Orita, M., Ohno, K., & Niimi, T. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.006 · Cited by 55
Valko, K. L., Nunhuck, S., & Hill, A. P. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22323 · Cited by 63
Schroeder, C. E., Yao, T., Sotsky, J. B., Smith, R. A., Roy, S., Chu, Y., Guo, H., Tower, N. A., Noah, J. W., McKellip, S. N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501203v · Cited by 55
Soares, R. R., da Silva, J. M. F., Carlos, B. C., da Fonseca, C. C., de Souza, L. S. A., Lopes, F. V., Dias, R. M. P., Moreira, P. O. L., Abramo, C., Viana, G. H. R., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.014 · Cited by 54
Christiansen, E., Due‐Hansen, M. E., Urban, C., Grundmann, M., Schröder, R. J., Hudson, B. D., Milligan, G., Cawthorne, M. A., Kostenis, E., Kassack, M. U., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002026 · Cited by 58
A modular lead-oriented synthesis of diverse piperazine, 1,4-diazepane and 1,5-diazocane scaffolds
JAMES, T. N., MacLellan, P., Burslem, G. M., Simpson, I. D., Grant, J., Warriner, S. L., Sridharan, V., & Nelson, A. S. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42512f · Cited by 54
One-pot synthesis of highly functionalized pyrimido[1,2-b]indazoles via 6-endo-dig cyclization
Palaniraja, J., Roopan, S. M., & Rayalu, G. M. (2016) · RSC Advances · doi:10.1039/c6ra02596j · Cited by 54
Improvement in aqueous solubility achieved via small molecular changes
Walker, M. A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.041 · Cited by 60
Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs
Leeson, P. D. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00044 · Cited by 57
Self-citationPenzo, M., Heras-Dueña, L. D. L., Mata-Cantero, L., Diaz-Hernandez, B., Vazquez-Muñiz, M.-J., Ghidelli, S., Drewes, G., Fernández‐Álvaro, E., & Baker, D. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-42801-x · Cited by 55
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)
Chan, B. K., Seward, E. M., Lainchbury, M. D., Brewer, T. F., An, L., Blench, T., Cartwright, M. W., Chan, G. K. Y., Choo, E. F., Drummond, J., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00473 · Cited by 54
Lang, S. B., Wiles, R. J., Kelly, C. B., & Molander, G. A. (2017) · Angewandte Chemie · doi:10.1002/ange.201709487 · Cited by 57
In SilicoPhysicochemical Parameter Predictions
Wenlock, M. C., & Barton, P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300537k · Cited by 55
“94 Hughes et al. reported that a toxicological outcome in rat and dog in vivo toleration studies was more common for nonpolar lipophilic compounds (i.e., clog P > 3 and total PSA < 75 Å 2 ).”
BackgroundRepurposing the Antihistamine Terfenadine for Antimicrobial Activity against Staphylococcus aureus
Perlmutter, J. I., Forbes, L., Krysan, D. J., Ebsworth-Mojica, K., Colquhoun, J. M., Wang, J. L., Dunman, P. M., & Flaherty, D. P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010682 · Cited by 65
Drug-like Properties and Fraction Lipophilicity Index as a combined metric
Tsantili‐Kakoulidou, A., & Demopoulos, V. J. (2021) · ADMET & DMPK · doi:10.5599/admet.1022 · Cited by 62
“The concept of drug-likeness was further advanced to address drug safety by normalizing affinity to size or/and lipophilicity, as reflected in metrics like Ligand Efficiency (LE), Lipophilic Ligand Efficiency (LLE) and Ligand Efficiency Dependent Lipophilicity (LELP) [1,14-16].”
BackgroundRecent progress in organophotoredox reaction
Liu, Q., Huo, C., Fu, Y. H., & Du, Z. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob00807f · Cited by 53
Fagerberg, J. H., & Bergström, C. A. S. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.45 · Cited by 57
Benbow, J. W., Aubrecht, J., Banker, M. J., Nettleton, D. O., & Aleo, M. D. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.05.016 · Cited by 55
A Chemogenomic Analysis of Ionization Constants—Implications for Drug Discovery
Manallack, D. T., Prankerd, R. J., Nassta, G. C., Ursu, O., Oprea, T. I., & Chalmers, D. K. (2013) · ChemMedChem · doi:10.1002/cmdc.201200507 · Cited by 53
Fauber, B. P., René, O., Boenig, G. D. L., Burton, B., Deng, Y., Eidenschenk, C., Everett, C., Gobbi, A., Hymowitz, S. G., Johnson, A. R., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.048 · Cited by 59
Schiffler, M. A., Antonysamy, S., Bhattachar, S., Campanale, K. M., Chandrasekhar, S., Condon, B., Desai, P. V., Fisher, M. J., Groshong, C., Harvey, A. K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01249 · Cited by 53
Drug Metabolism and Pharmacokinetics Quick Guide
Khojasteh, S. C., Wong, H. H., & Hop, C. E. C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5629-3 · Cited by 75
Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring
Onawole, A. T., Kolapo, T. U., Sulaiman, K. O., & Adegoke, R. O. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.11.006 · Cited by 56
Jagannathan, R. (2019) · ACS Omega · doi:10.1021/acsomega.8b01764 · Cited by 61
Oliveira, C., Bagetta, D., Cagide, F., Teixeira, J., Amorim, R., Silva, T., Garrido, J. M. P. J., Remião, F., Uriarte, E., Oliveira, P. J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.026 · Cited by 57
Banks, W. A., & Greig, N. H. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0436 · Cited by 62
Advancing bioinformatics with language models: components, applications, and perspectives
Liu, J., Yang, M., Yu, Y., Xu, H., Wang, T., Li, K., & Zhou, X. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag367 · Cited by 72
Dossetter, A. G. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.04.077 · Cited by 52
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie · doi:10.1002/ange.201002238 · Cited by 52
LaPlante, S. R., Aubry, N., Bolger, G. T., Bonneau, P. R., Carson, R. J., Coulombe, R., Sturino, C. F., & Beaulieu, P. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008714 · Cited by 52
Mikami, S., Kitamura, S., Negoro, N., Sasaki, S., Suzuki, M., Tsujihata, Y., Miyazaki, T., Ito, R., Suzuki, N., Miyazaki, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016123 · Cited by 53
Wang, H., Huwaimel, B., Verma, K., Miller, J. E., Germain, T., Kinarivala, N., Pappas, D., Brookes, P. S., & Trippier, P. C. (2017) · ChemMedChem · doi:10.1002/cmdc.201700196 · Cited by 58
Sikari, R., Sinha, S., Chakraborty, G., Das, S., van Leest, N. P., & Paul, N. D. (2019) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201900545 · Cited by 52
Fan, S., Iorga, B. I., & Beckstein, O. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00267-z · Cited by 52
Huffman, B. J., Chen, S., Schwarz, J. L., Plata, R. E., Chin, E. N., Lairson, L. L., Houk, K. N., & Shenvi, R. A. (2020) · Nature Chemistry · doi:10.1038/s41557-019-0413-8 · Cited by 52
Smith, A. L., D’Angelo, N. D., Bo, Y. Y., Booker, S. K., Cee, V. J., Herberich, B., Hong, F., Jackson, C. L. M., Lanman, B. A., Liu, L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300184s · Cited by 54
IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines
Buckley, G. M., Fosbeary, R., Fraser, J. L., Gowers, L., Higueruelo, A. P., James, L. A., Jenkins, K., Mack, S. R., Morgan, T., Parry, D. M., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.042 · Cited by 51
Evolution of the physicochemical properties of marketed drugs: can history foretell the future?
Faller, B., Ottaviani, G., Ertl, P., Berellini, G., & Collis, A. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.003 · Cited by 51
Damont, A., Médran‐Navarrete, V., Cacheux, F., Kühnast, B., Pottier, G., Bernards, N., Marguet, F., Puech, F., Boisgard, R., & Dollé, F. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00932 · Cited by 51
Deeming, A. S., Russell, C. J., & Willis, M. C. (2014) · Angewandte Chemie · doi:10.1002/ange.201409283 · Cited by 51
Naidoo, D., Roy, A., Kar, P., Mutanda, T., & Anandraj, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1794972 · Cited by 55
“The compounds carrageenan, eucapsitrione, cylindrospermopsin and deoxycylindrospermopsin exhibited LLE values greater than the proposed acceptable threshold (Leeson & Springthorpe, 2007; Ul Qamar et al., 2020).”
BackgroundJimenez, J., Boyall, D., Brenchley, G., Collier, P. N., Davis, C. J., Fraysse, D., Keily, S. B., Henderson, J. L., Miller, A., Pierard, F. Y. T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301465a · Cited by 50
Zimmermann, M. O., Lange, A., Wilcken, R., Cieslik, M. B., Exner, T. E., Joerger, A. C., Koch, P., & Boeckler, F. M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.20 · Cited by 58
Jadhavar, P. S., Patel, K. I., Dhameliya, T. M., Saha, N., Vaja, M. D., Krishna, V. S., Sriram, D., & Chakraborti, A. K. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103774 · Cited by 50
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.